List of Tables
Table 1. Global Immunotherapy Drugs for Neuroblastoma Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Immunotherapy Drugs for Neuroblastoma Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Immunotherapy Drugs for Neuroblastoma Market Competitive Situation by Manufacturers in 2024
Table 4. Global Immunotherapy Drugs for Neuroblastoma Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Immunotherapy Drugs for Neuroblastoma Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Immunotherapy Drugs for Neuroblastoma Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Immunotherapy Drugs for Neuroblastoma, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Immunotherapy Drugs for Neuroblastoma, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Immunotherapy Drugs for Neuroblastoma, Product Type & Application
Table 12. Global Key Manufacturers of Immunotherapy Drugs for Neuroblastoma, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Immunotherapy Drugs for Neuroblastoma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy Drugs for Neuroblastoma as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Immunotherapy Drugs for Neuroblastoma Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K Units)
Table 18. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2025)
Table 19. Global Immunotherapy Drugs for Neuroblastoma Sales by Region (2026-2031) & (K Units)
Table 20. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2026-2031)
Table 21. Global Immunotherapy Drugs for Neuroblastoma Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2025)
Table 23. Global Immunotherapy Drugs for Neuroblastoma Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2026-2031)
Table 25. North America Immunotherapy Drugs for Neuroblastoma Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
Table 27. North America Immunotherapy Drugs for Neuroblastoma Sales by Country (2026-2031) & (K Units)
Table 28. North America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
Table 32. Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2026-2031) & (K Units)
Table 33. Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Immunotherapy Drugs for Neuroblastoma Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Immunotherapy Drugs for Neuroblastoma Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Immunotherapy Drugs for Neuroblastoma Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Immunotherapy Drugs for Neuroblastoma Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Immunotherapy Drugs for Neuroblastoma Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Immunotherapy Drugs for Neuroblastoma Sales (K Units) by Type (2020-2025)
Table 51. Global Immunotherapy Drugs for Neuroblastoma Sales (K Units) by Type (2026-2031)
Table 52. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
Table 53. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2026-2031)
Table 54. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2020-2025)
Table 57. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2026-2031)
Table 58. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Type (2020-2025)
Table 59. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Type (2026-2031)
Table 60. Global Immunotherapy Drugs for Neuroblastoma Sales (K Units) by Application (2020-2025)
Table 61. Global Immunotherapy Drugs for Neuroblastoma Sales (K Units) by Application (2026-2031)
Table 62. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
Table 63. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2026-2031)
Table 64. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2020-2025)
Table 67. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2026-2031)
Table 68. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Application (2020-2025)
Table 69. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Application (2026-2031)
Table 70. United Therapeutics Company Information
Table 71. United Therapeutics Description and Business Overview
Table 72. United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product
Table 74. United Therapeutics Recent Developments/Updates
Table 75. Y-mAbs Therapeutics Company Information
Table 76. Y-mAbs Therapeutics Description and Business Overview
Table 77. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product
Table 79. Y-mAbs Therapeutics Recent Developments/Updates
Table 80. EUSA Pharma Company Information
Table 81. EUSA Pharma Description and Business Overview
Table 82. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product
Table 84. EUSA Pharma Recent Developments/Updates
Table 85. ANI Pharmaceuticals Company Information
Table 86. ANI Pharmaceuticals Description and Business Overview
Table 87. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product
Table 89. ANI Pharmaceuticals Recent Developments/Updates
Table 90. Baxter Healthcare Company Information
Table 91. Baxter Healthcare Description and Business Overview
Table 92. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product
Table 94. Baxter Healthcare Recent Developments/Updates
Table 95. Ingenus Pharmaceuticals Company Information
Table 96. Ingenus Pharmaceuticals Description and Business Overview
Table 97. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product
Table 99. Ingenus Pharmaceuticals Recent Developments/Updates
Table 100. Pfizer Company Information
Table 101. Pfizer Description and Business Overview
Table 102. Pfizer Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Pfizer Immunotherapy Drugs for Neuroblastoma Product
Table 104. Pfizer Recent Developments/Updates
Table 105. Hikma Pharmaceuticals Company Information
Table 106. Hikma Pharmaceuticals Description and Business Overview
Table 107. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product
Table 109. Hikma Pharmaceuticals Recent Developments/Updates
Table 110. Teva Pharmaceuticals Company Information
Table 111. Teva Pharmaceuticals Description and Business Overview
Table 112. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product
Table 114. Teva Pharmaceuticals Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Immunotherapy Drugs for Neuroblastoma Distributors List
Table 118. Immunotherapy Drugs for Neuroblastoma Customers List
Table 119. Immunotherapy Drugs for Neuroblastoma Market Trends
Table 120. Immunotherapy Drugs for Neuroblastoma Market Drivers
Table 121. Immunotherapy Drugs for Neuroblastoma Market Challenges
Table 122. Immunotherapy Drugs for Neuroblastoma Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Product Picture of Immunotherapy Drugs for Neuroblastoma
Figure 2. Global Immunotherapy Drugs for Neuroblastoma Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Immunotherapy Drugs for Neuroblastoma Market Share by Type: 2024 & 2031
Figure 4. Dinutuximab Product Picture
Figure 5. Naxitamab Product Picture
Figure 6. Other Product Picture
Figure 7. Global Immunotherapy Drugs for Neuroblastoma Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Immunotherapy Drugs for Neuroblastoma Market Share by Application: 2024 & 2031
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Other
Figure 12. Global Immunotherapy Drugs for Neuroblastoma Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Immunotherapy Drugs for Neuroblastoma Market Size (2020-2031) & (US$ Million)
Figure 14. Global Immunotherapy Drugs for Neuroblastoma Sales (2020-2031) & (K Units)
Figure 15. Global Immunotherapy Drugs for Neuroblastoma Average Price (US$/Unit) & (2020-2031)
Figure 16. Immunotherapy Drugs for Neuroblastoma Report Years Considered
Figure 17. Immunotherapy Drugs for Neuroblastoma Sales Share by Manufacturers in 2024
Figure 18. Global Immunotherapy Drugs for Neuroblastoma Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Immunotherapy Drugs for Neuroblastoma Players: Market Share by Revenue in Immunotherapy Drugs for Neuroblastoma in 2024
Figure 20. Immunotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Immunotherapy Drugs for Neuroblastoma Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2031)
Figure 23. North America Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2031)
Figure 24. United States Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2031)
Figure 27. Europe Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2031)
Figure 28. Germany Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2031)
Figure 35. China Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2031)
Figure 43. Latin America Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2031)
Figure 44. Mexico Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2031)
Figure 49. Turkey Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of Immunotherapy Drugs for Neuroblastoma by Type (2020-2031)
Figure 53. Global Revenue Market Share of Immunotherapy Drugs for Neuroblastoma by Type (2020-2031)
Figure 54. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of Immunotherapy Drugs for Neuroblastoma by Application (2020-2031)
Figure 56. Global Revenue Market Share of Immunotherapy Drugs for Neuroblastoma by Application (2020-2031)
Figure 57. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Application (2020-2031)
Figure 58. Immunotherapy Drugs for Neuroblastoma Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
